{
  "source": "PA-Notification-Sovaldi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1127-17\nProgram Prior Authorization/Notification\nMedication Sovaldi® (sofosbuvir)\nP&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014, 2/2015, 8/2015, 2/2016, 2/2017, 2/2018,\n2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nSovaldi® (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor\nindicated for the treatment of:\n• Adult patients with genotype 1, 2, 3, or 4 chronic HCV infection without cirrhosis or with\ncompensated cirrhosis as a component of a combination antiviral treatment regimen.\n• Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without\ncirrhosis or with compensated cirrhosis in combination with ribavirin.\n2. Coverage Criteriaa:\nA. Sovaldi in combination with ribavirin with or without peginterferon alfa:\n1. Sovaldi will be approved based on one of the following criteria:\na. All of the following:\n(1) Diagnosis of chronic hepatitis C genotype 1 or 4 infection\n-AND-\n(2) Used in combination with ribavirin\n-AND-\n(3) One of the following:\n(a) Used in combination with peginterferon alfa\n-OR-\n(b) Both of the following:\n1) Patient is ineligible for peginterferon alfa therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n2) Patient has genotype 1 infection\n-AND-\n(4) Patient has not experienced failure with a previous treatment regimen that\nincludes Sovaldi\n-AND-\n(5) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)\n-OR-\nb. All of the following:\n(1) Diagnosis of chronic hepatitis C genotype 2 or 3 infection\n-AND-\n(2) Used in combination with ribavirin\n-AND-\n(3) Patient has not experienced failure with a previous treatment regimen that\nincludes Sovaldi\n-OR-\nc. All of the following:\n(1) Diagnosis of chronic hepatitis C genotype 1, 2, 3, or 4 infection\n-AND-\n(2) One of the following:\n(a) Diagnosis of hepatocellular carcinoma\n-OR-\n(b) Patient has decompen",
    "-\nc. All of the following:\n(1) Diagnosis of chronic hepatitis C genotype 1, 2, 3, or 4 infection\n-AND-\n(2) One of the following:\n(a) Diagnosis of hepatocellular carcinoma\n-OR-\n(b) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)\n-AND-\n(3) Patient is an active candidate on the waiting list for a liver transplant\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(4) Used in combination with ribavirin\n-AND-\n(5) Patient has not experienced failure with a previous treatment regimen that\nincludes Sovaldi\nFor GENOTYPES 1 and 4 in combination with peginterferon alfa and ribavirin:\nAuthorization will be issued for 12 weeks.\nFor GENOTYPE 1 in combination with ribavirin and ineligible for pegylated\ninterferon alfa: Authorization will be issued for 24 weeks.\nFor GENOTYPE 2 in combination with ribavirin: Authorization will be issued for\n12 weeks.\nFor GENOTYPE 3 in combination with ribavirin: Authorization will be issued for\n24 weeks.\nFor GENOTYPES 1, 2, 3, or 4 in combination with ribavirin in patients with\nhepatocellular carcinoma OR decompensated liver disease and awaiting liver\ntransplantation: Authorization will be issued for 48 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class\n• Supply limits, step therapy and medical necessity may be in place.\n4. References:\n1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases\nSociety of America. Recommendations for Testing, Managing, an",
    "]. Foster City, CA: Gilead Sciences, Inc.; March 2020.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases\nSociety of America. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttp://www.hcvguidelines.org/full-report-view. Accessed April 10, 2025.\nProgram Prior Authorization/Notification - Sovaldi™ (sofosbuvir)\nChange Control\n2/2014 New program.\n4/2014 Added criteria for Sovaldi + pegineterferon alfa + ribavirin for genotype\n3. Added criteria for Sovaldi + ribavirin for genotype 4. Added criteria\nfor HCV reinfection after liver transplantation.\n5/2014 Added criterion requiring that the patient has not tried a previous\n© 2025 UnitedHealthcare Services, Inc.\n3\nregimen with Sovaldi or has demonstrated intolerance to\nSovaldi/interferon/ribavirin.\nRemoved symptomatic hepatitis C induced cryoglobulinemia as an\n8/2014 option to prove interferon ineligibility. Added criterion requiring that\npatient is without decompensated disease throughout, except where\ncriteria has been revised to allow in decompensated patients awaiting\nliver transplant.\n12/2014 Administrative correction.\n2/2015 Updated background and references. Revised Sovaldi in combination\nwith Olysio section to reflect revised Olysio prescribing information.\n8/2105 Added criteria for combination therapy with Daklinza (daclatasavir).\n2/2016 Annual review with no clinical changes. Updated references.\n2/2017 Annual review. Removal of Sovaldi/ribavirin combination for post\ntransplant therapy in genotypes 1, 3, and 4 as no longer recommended\nby guidelines. Updated approval duration to 24 weeks for genotype 2\npost liver transplant. Added genotype 1 to criteria for combination\ntherapy with Daklinza (daclatasavir).\n2/2018 Annual review with no change to coverage criteria. Updated references.\n2/2019 Removed use with Olysio (simeprevir) to reflect market withdrawal.\nUpdated criteria to remove reinfection after liver transplant for\ngenotype 2. Updated approval durations.\n2/2020 ",
    " references.\n2/2019 Removed use with Olysio (simeprevir) to reflect market withdrawal.\nUpdated criteria to remove reinfection after liver transplant for\ngenotype 2. Updated approval durations.\n2/2020 Annual review. Clarification to genotype 1 or 4 length of therapy with\nribavirin +/- peginterferon. Removed criteria for use with Daklinza, as\nDaklinza is now off the market. Updated background and references.\n2/2021 Annual review. No changes to clinical coverage criteria. Background\nand references updated.\n2/2022 Annual review. No changes to clinical coverage criteria. References\nupdated.\n2/2023 Annual review without changes to clinical coverage criteria. Added\nstate mandate and updated references.\n5/2023 Simplified peginterferon eligibility requirements. Updated references.\n5/2024 Annual review. Updated background and references.\n5/2025 Annual review without changes to coverage criteria. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}